News

Novartis presents 2.5-year kidney function data for atrasentan in IgA nephropathy, evaluating durable eGFR preservation beyond proteinuria reduction.

BIIB122 fails to slow motor progression in Phase 2b Parkinson's study despite strong target engagement in 648 patients.

Akeso's ivonescimab OS data from HARMONi-6 heads to ASCO plenary as a head-to-head Phase III trial against tislelizumab in...

TaiMed's TMB-365/380 HIV Study completes Phase 2b enrollment ahead of schedule with viral suppression data matching expectations after two...

RESP-X shows reduced exacerbations in Phase IIa bronchiectasis trial, with 100% target coverage and lung penetration confirmed.

Tedopi Plus Pembrolizumab Improves Survival in Platinum-Resistant Ovarian Cancer with HR of 0.53 in Phase 2 trial.

Novartis presents 2.5-year eGFR data from ALIGN trial of atrasentan in IgA Nephropathy, alongside iptacopan and zigakibart findings in...

LUMA trial of BIIB122 failed to slow Parkinson's disease progression in 648 participants despite confirmed target engagement over 144...

BioCardia's CardiAMP shows 179-second exercise gain in refractory angina trial, with sustained angina reduction over two years of follow-up.

Infex's RESP-X Phase IIa bronchiectasis study shows efficacy signal, lung deposition, and clean safety profile supporting Phase IIb/III advancement.